ArticleCurrent medical imaging2025
CT-based Radiomics of Intratumoral and Peritumoral Regions to Predict the Recurrence Risk in Patients with Non-muscle-invasive Bladder Cancer within Two Years after TURBT.
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Composite Risk Score Based on VI-RADS, Tumor Contact Length, and CYFRA 21-1 for Prognostic Stratification in Bladder Cancer.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPredicting the recurrence risk of NMIBC after TURBT is crucial for individualized clinical treatment.
objectiveThe objective of this study is to evaluate the ability of radiomic feature analysis of intratumoral and peritumoral regions based on computed tomography (CT) imaging to predict recurrence in non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder tumor (TURBT).
methodsA total of 233 patients with NMIBC who underwent TURBT were retrospectively analyzed. Within the intratumoral and peritumoral regions of the venous phase images, 1316 radiomics features were extracted. Feature selection was used to identify a set of top recurrence-associated features within the training cohort. Three models were constructed to predict recurrence for a given patient using Random Forest (RF): Model 1 was based on the radiomics features set from the intratumoral region, Model 2 was based on a combination of intratumoral and peritumoral regions, and Model 3 combined the radiomics features from Model 2 and clinical factors. The three models were then independently tested on internal and external cohorts, and their performance was evaluated. We also employed the bootstrap method on the internal cohort to further validate the performance of the model.
resultsCombining intratumoral and peritumoral regions, Model 2 yielded a higher area under the receiver operator characteristic curves (AUC) than Model 1, with 0.826 AUCs of the training cohort. After adding clinical factors, the predictive performance of Model 3 for postoperative recurrence of NMIBC was further improved, and the AUCs of the training, internal, and external validation cohorts of Model 3 were 0.860 (95% CI: 0.829-0.954), 0.829 (0.812-0.863), and 0.805 (0.652-0.840), respectively (all p>0.05). The bootstrap value of Model 3 on the internal cohort was 0.852. Model 3 stratified patients into high- and low-risk groups with significantly different recurrence-free survival (RFS) (p<0.001).
conclusionRadiomic features derived from intratumoral regions can predict the 2-year recurrence risk following TURBT in patients with NMIBC. The predictive performance is further enhanced when combined with radiomic features from peritumoral regions and clinical risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.